Precigen Inc. (PGEN) has emerged as a notable biotechnology company following the full FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis in August 2025. With commercial momentum building, payer coverage expanding, and long-term durability data reinforcing the therapy's impact, attention now shifts to the company's upcoming catalysts.
These include the ongoing European regulatory review, further adoption metrics from the PAPZIMEOS Patient Hub, and clinical progress across its AdenoVerse immunotherapy pipeline. Together, these milestones have the potential to shape the company's trajectory in both the near and medium term.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.